Chantal Plante (PHAC)
The Task Force held its first hybrid meeting in Calgary June 2022. For those who could not be present, the meeting was also broadcasted via videoconference. Dr. Wilson and Dr. Grad opened the meeting and Task Force members approved the agenda. Dr. Wilson provided some brief guidelines on the proceedings of this meeting.
Dr. Wilson went through some housekeeping items such as the COVID-19 protocol for those attending in person. Roundtable introductions were done, and Dr. Wilson welcomed new staff of the Task Force.
The interim co-Chairs thanked everyone for their participation.
Ms. Pillay and Dr. Reynolds presented updates on the Cervical Cancer guideline.
Mr. Traversy presented on the Evidence to Decision (EtD) framework and ensuing recommendations for behavioural interventions for smoking cessation.
Dr. Abou-Setta presented an update on the methods manual, the thresholds discussion, along with cancer outcomes.
Dr. Wilson introduced the issue and prepared the group for the upcoming decisions regarding cardiovascular disease (CVD) and hypertension topics.
Ms. Beckett and Ms. Buttar provided updates on recent KT activities and initiatives. This update included information on recently published and upcoming guidelines, new and upcoming KT tools, dissemination activities, Task Force projects, TFPAN (lesson learned and changes to the methods), recommendations from the Task Force annual evaluation as well a review of the KT budget and related priorities.
Dr. Allan and Dr. Korownyk (PEER Group) presented an overview PEER’s mandate, their guideline work and the current update to their lipid guideline.
Ms. Barnhardt presented an update on the recent work of the Communications team and their ongoing initiatives specifically on the PPP Depression communications approach.
Dr. Klarenbach presented an update and discussed the draft objectives of using OncoSim (not seeking approval).
Dr. Grad led a discussion to seek tentative decision on CVD in light of the PEER group’s presentation.
Dr. Wilson and Ms. Garitty presented on the KQs of the Hypertension guideline.
Ms. Limburg presented on the Topics, specifically seeking TF approval of Topic WGs recommendation to send AAA for confirmation and seeking confirmation on the final decision on the 2023/24 topic short list. Ms. Limburg also provided an update on the annual surveillance (Prevention plus) and the next steps for the WG.
The guideline Working Group Chairs provided brief updates for the following guidelines: Prostate Cancer Screening, Depression (PPP, adult and child/adolescent), Fragility Fractures, Opioids, and Equity.
Dr. Grad thanked everyone for attending. The June 2022 Task Force hybrid meeting was adjourned.